Key facts
- Notable investors include Kurma Partners, Pureos Bioventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Evidence Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Evidence Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Evidence Bio
Developer of therapeutic strategies for mucosal disorders designed to translate fundamental academic research into tangible clinical services for complex disease pathophysiology, such as respiratory diseases and other inflammatory conditions. The company is currently operating in Stealth Mode.
- Sector
- Healthcare
- HQ
- Toulouse, France
- Founded
- 2025
- Employees
- 3
- Ownership
- Privately Held (backing)
Evidence Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Evidence Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Evidence Bio in its N-PORT filings yet. We sweep new filings monthly.